Immunosuppression (IS) with antithymocyte globulin (ATG) and ciclosporine A (CsA) is the treatment of choice for patients (pts.) with acquired severe aplastic anaemia who are not eligible for allogeneic stem cell transplantation. However, still there is a proportion of 20-30 % of pts. failing to respond. Response is often slow and incomplete. Therefore, it seems reasonable to evaluate whether combinations of standard IS with haematopoietic growth factors will lead to improvement of response rate and quality of response and to shortened time to response. In this trial the effect of ancestim was evaluated in pts also receiving ATG, CsA and filgrastim (G-CSF 5 µg/kg/day). Pts. were randomised to receive either no additional treatment (control group) or ancestim (35 µg/kg/tiw in the first week, then 50 µg/kg tiw). Filgrastim and ancestim were started on day 8 and continued through a complete response or day 240. Patients in the ancestim group received premedication with cetirizine, ranitidine and salbutamol. By March 24, 2000, 20 patients were enrolled (filgrastim group n = 9, filgrastim + ancestim group n = 11). Two pts in the control group died, and one discontinued due to a treatment-refractory fungal infection. In the ancestim group, 6 pts experienced allergic reactions between day 14 and 50 including hypotension with unconsciousness requiring epinephrine in 1 pt. The causal relationship between these events and ancestim was not clear in all instances. Some events might be due to ATG-induced serum sickness, as 2 of them resolved without treatment. However, for safety reasons it was decided to discontinue ancestim in pts with an allergic event. Because of these adverse events and the effect of the high discontinuation rate in both treatment arms on the statistical power and sample-size calculations, the study's independent Data Monitoring Committee recommended that the trial be closed. Surviving pts were followed until day 120. In the control group 5 pts responded (1 CR and 4 PR) and 4 patients did not respond (1 NR died, 1 NR had fungal infection) One subject developed a PR, then relapsed and died before 120 days. In the ancestim group 9 pts responded (3 CR, 6 PR) and 2 pts did not respond. No pt in the ancestim group died. In this study the incidence of allergic reactions which potentially were related to ancestim was higher than in a trial of ancestim as single agent or in combination with filgrastim in AA pts who had previously failed ATG (n=93). This might be due to the combination of ancestim with IS, in particular with ATG. Trials of ancestim in combination with ATG for treatment of AA might require a different treatment schedule.
